# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


Gastric Lymphoma

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 12 results.
Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma
Status: Recruiting
Last Changed: Mar 09, 2020
First Received: Sep 21, 2018
Disease(s): Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Intervention(s): Radiation Therapy
Locations: M D Anderson Cancer Center, Houston, Texas, United States
First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL
Status: Recruiting
Last Changed: Mar 25, 2016
First Received: Mar 17, 2015
Disease(s): Gastric Diffuse Large B-cell Lymphoma
Intervention(s): Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
Locations: National Health Research Institutes, Zhunan, Miaoli County, Taiwan
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
Status: Recruiting
Last Changed: Sep 20, 2019
First Received: Sep 20, 2019
Disease(s): Follicular Lymphoma (Gastric or Duodenal), Marginal Zone Lymphoma (Gastric or Duodenal)
Intervention(s): Radiation Therapy
Locations: Department of Radiation Oncology, Münster, North Rhine-Westphalia, Germany
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Status: Recruiting
Last Changed: Mar 19, 2020
First Received: Jun 18, 2008
Disease(s): Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
Intervention(s): Temsirolimus, Temsirolimus, Sunitinib, Sunitinib, Axitinib
Locations: Dr. med. Harald Held, Neumuenster, Schleswig-holstein, Germany
Dr. med. Hans Wilhelm Duebbers, Ahaus, Germany
Dr. Ludwig Fischer von Weikersthal, Amberg, Germany
Group Practice Doctors Klausmann, Aschaffenburg, Germany
Studienzentrum Drs. Klausmann / Dr. Welslau, Haematologie-Onkologie-Diabetologie, Aschaffenburg, Germany
... and 71 other locations.
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma
Status: Recruiting
Last Changed: Jan 27, 2020
First Received: Dec 14, 2018
Disease(s): Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
Intervention(s): GZ17-6.02
Locations: HonorHealth Research Institute, Scottsdale, Arizona, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
Status: Recruiting
Last Changed: May 20, 2020
First Received: Jun 14, 2018
Disease(s): Solid Tumor, Lymphoma, Thymic Carcinoma and Thymoma, Mesothelioma, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Lung, Esophageal Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Cervical Cancer, Gastric Cancer, Melanoma, Acute Myeloid Leukemia, Pancreatic Carcinoma, Non Hodgkin Lymphoma
Intervention(s): VMD-928 300-mg Capsules
Locations: City of Hope National Medical Center, Duarte, California, United States
Atlantic Health System, Morristown Medical Center, Morristown, New Jersey, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Safety Study of SGN-TGT (SEA-TGT) in Patients With Advanced Cancer
Status: Recruiting
Last Changed: Aug 04, 2020
First Received: Feb 05, 2020
Disease(s): Non-small Cell Lung Cancer, Gastric Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma
Intervention(s): SGN-TGT, pembrolizumab
Locations: Providence Portland Medical Center, Portland, Oregon, United States
Hillman Cancer Center / University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Recruiting
Last Changed: Aug 11, 2020
First Received: Jun 08, 2015
Disease(s): Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Kidney Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Ovarian Carcinoma, Pancreatic Carcinoma, Plasma Cell Myeloma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Plasma Cell Myeloma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Recurrent Uterine Corpus Cancer, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer
Intervention(s): Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Mobile Infirmary Medical Center, Mobile, Alabama, United States
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
... and 1329 other locations.
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Recruiting
Last Changed: Jun 07, 2019
First Received: Apr 20, 2015
Disease(s): Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Splenic Mantle Cell Lymphoma
Intervention(s): Akt/ERK Inhibitor ONC201, Laboratory Biomarker Analysis, Pharmacological Study
Locations: M D Anderson Cancer Center, Houston, Texas, United States
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
Status: Recruiting
Last Changed: May 02, 2017
First Received: Feb 07, 2017
Disease(s): Stage IV Gastric Carcinoma, Stage IV Nasopharyngeal Carcinoma, T-Cell Lymphoma Stage IV, Stage IV Adult Hodgkin Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma
Intervention(s): Fludarabine, Cyclophosphamide, Interleukin-2
Locations: The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China